Lineage B.1.1.7

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Jeudi, août 5, 2021
Company, GlaxoSmithKline, Emergency Use Authorization, Royal commission, Committee, Biologics license application, European Commission, Union, United Arab Emirates, Food, Intention, IND, Medicine, Lineage B.1.1.7, European Medicines Agency, GSK, Patient, Maa, COVID-19, CHMP, Severe acute respiratory syndrome coronavirus 2, EMA, BLA, SAN, Joint, Food and Drug Administration, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Biotechnology, BioRxiv, Hospital, Safety, EUA, Death, Ageing, Nivolumab, GLOBE, Pharmaceutical industry, Vaccine

SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
  • The rolling review process is expected to be complete in the second half of 2021.
  • Together with GSK, the Company plans to submit a Biologics License Application (BLA) to the FDA in the second half of 2021.
  • The trial was initiated in June and data are now expected in the second half of 2021.

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine

Retrieved on: 
Jeudi, août 5, 2021
Infection, B cell, Lymph, Clinical trial, World Health Organization, U.S. Securities and Exchange Commission, Vaccine, Coronavirus, Nanoparticle, SII, COVID-19, Risk, Annual report, Drugs Controller General of India, Partnership, Lineage B.1.1.7, Review, Genetic engineering, Conversation, Serum Institute of India, Health, Analysis, Financial condition report, Severe acute respiratory syndrome coronavirus 2, EUL, Global health, Good, World, Good manufacturing practice, Chemistry, SEC, Antibody, COVAX, Novavax, Novavax COVID-19 vaccine, NVAX, Antigen presentation, Safety, Biotechnology, Result, Vaccination, Security (finance), Disease, Pharmaceutical industry

GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced that the companies have filed regulatory submissions for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submissions were made to the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines.

Key Points: 
  • Ltd. (SII), today announced that the companies have filed regulatory submissions for emergency use authorization of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
  • The submissions were made tothe Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines.
  • SII and Novavax have now completed the submission of all modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls data.
  • A submission to the World Health Organization (WHO) for emergency use listing (EUL) based on the DCGI submission is expected to be filed in August.

Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test

Retrieved on: 
Jeudi, août 5, 2021
Company, Itch, POC, Chief executive officer, FSE, OTC Markets Group, Patent, Inflammation, Technology, United States, Machine learning, IOT, Severe acute respiratory syndrome, Partnership, Lineage B.1.1.7, Airport, Coronavirus, Apple, Intelligence, Delta, COVID-19, Twitter, School, Pain, Restaurant, Food and Drug Administration, Netflix, Work, Platform, Spokane Public Facilities District, Novel coronavirus, Naxos Island National Airport, Hospital, Education, Microsoft, Vaccine, Pharmaceutical industry

Company To Begin Embedding Solution Onto Each 15-Minute COVID-19 Rapid Antigen Test Cartridge

Key Points: 
  • Following the FDA-EUA approval for point-of-care use, this first-of-its-kind, the smart-enabled AcuVid saliva test will be submitted for FDA-EUA approval for at-home use.
  • "The AcuVid COVID-19 Rapid Antigen Saliva Test, powered by Afero, has always had the main goal of helping communities safely and securely stay open or re-open during this COVID-19 pandemic," shared Joe Britt, CEO of Afero.
  • In July 2021, Therma Bright announced that it had completed its clinical trials of its AcuVid COVID-19 Rapid Antigen Saliva Test for the successful detection of the Novel Coronavirus SARS CoV-2.
  • Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus

Retrieved on: 
Jeudi, août 5, 2021
Nau, Cisplatin, Cancer, Drug discovery, MBio, MA, Fatality, Clinical trial, Fibroblast growth factor receptor, Irofulven, Polymerase chain reaction, Lineage B.1.1.7, Doxorubicin, Infection, University of Arizona, Plaque, Therapy, Chief executive officer, Northern Arizona University, Laboratory, National Institute, Severe acute respiratory syndrome coronavirus 2, National Institutes of Health, Degenerative disease, Dana–Farber Cancer Institute, App, Breast, RNA, Pathogen, Prostate cancer, Renal cell carcinoma, Company, Research, Student, Forward-looking statement, Allar, Jerusalem, Breast cancer, PARP, Virus, National Institute of Allergy and Infectious Diseases, Patient, COVID-19, Ovarian cancer, Poly (ADP-ribose) polymerase, Ixabepilone, Social media, Center, Nasdaq, DNA, Goal, Disease, Pharmaceutical industry

The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.

Key Points: 
  • The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.
  • The concentration of stenoparib required for virus inhibition was lower in the combination study with remdesivir than in the single agent study.
  • Stenoparib is a novel small molecule (oral), targeted inhibitor of Poly ADP-Ribose Polymerase (PARP), a key DNA damage repair enzyme active in cancer cells.
  • Forward-looking statements include statements concerning Allaritys plans, objectives, goals, future events, performance and/or other information that is not historical information.

Sixth Wave Detects UK and South African Variants of SARS-CoV-2

Retrieved on: 
Jeudi, juin 10, 2021
Variants of SARS-CoV-2, Lineage B.1.351, Lineage B.1.1.7, Vaccine, Medical specialties, Branches of biology, Medicine

The virus variants detected include the UK variant and the South African variant.

Key Points: 
  • The virus variants detected include the UK variant and the South African variant.
  • There are documented cases of new variants circumventing the human immune system and causing reinfection and drastically reduced efficacy of certain vaccines.
  • Sixth Wave continues to expand the capabilities of the AMIP diagnostic platform as it works on improving the specificity and sensitivity in their prototype devices.
  • Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries.

Scripps Research Institute testing shows Viraleze highly active against UK COVID strain

Retrieved on: 
Mardi, juin 1, 2021
Variants of SARS-CoV-2, Occupational safety and health, SARS-CoV-2, COVID-19, Variant of concern, Lineage B.1.1.7, Lineage B.1.351, Health, LloydsPharmacy

Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.

Key Points: 
  • Starpharma is alsotesting the Japan/Brazil and South African variants of COVID, with the results expected in the coming weeks.
  • The antiviral testing was conducted by the renowned Scripps Research Institute in the US, with the UK variant of SARS-CoV-2, which has been classified as a variant of concern.
  • The UK variant was recently reported to be responsible for over 98% of the positive COVID infections in England and linked to multiple outbreaks worldwide.
  • Viraleze is registered for sale in Europe and the UK, and is available through one of the UK's largest pharmacy chains, LloydsPharmacy.

Global is Going Mobile; Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Retrieved on: 
Jeudi, mai 20, 2021
Variants of SARS-CoV-2, Medical specialties, Branches of biology, Zoonoses, Health, Sarbecovirus, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Peplomer, Virus, Severe acute respiratory syndrome coronavirus, Antibody

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.
  • Investors and security holders are urged to read these documents free of charge on the SEC\'s web site at http://www.sec.gov .
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

ECDC releases new dashboard on SARS-CoV-2 variants

Retrieved on: 
Jeudi, mai 20, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Lineage B.1.617, Severe acute respiratory syndrome coronavirus, Lineage B.1.1.7

Data for the most recent reporting week have been excluded, as they may be incomplete.

Key Points: 
  • Data for the most recent reporting week have been excluded, as they may be incomplete.
  • The proportion of variants is only reliable when sequencing capacity is adequate (500 or 10% of total samples).
  • For TESSy data, no proportion of variants has been estimated where there is no reliable denominator available.
  • In addition, SARS-CoV-2 lineages B.1.617.1, B.1.617.2, and B.1.617.3, first reported in India in December 2020, have been increasingly detected in other countries.

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Retrieved on: 
Mardi, mai 18, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Zoonoses, Sarbecovirus, Medicine, Clinical medicine, Variants of SARS-CoV-2, XC2, Lineage B.1.1.7, COVID-19, Severe acute respiratory syndrome coronavirus, Monoclonal antibody

CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.

Key Points: 
  • CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.
  • \xe2\x80\x9cMonoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate COVID-19.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.
  • For more information please visit: https://www.celltrionhealthcare.com/en-us .\nCT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus.

Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern

Retrieved on: 
Mardi, mai 18, 2021
Variants of SARS-CoV-2, Coronaviridae, SARS-CoV-2, COVID-19 vaccines, Clinical trials, Sarbecovirus, Zoonoses, COVID-19 vaccine, Medical research, Lineage P.1, Lineage B.1.351, Lineage B.1.1.7

B.1.351 S-Trimer demonstrated broad neutralization against the original SARS-CoV-2 strain and variants of concern, specifically the South African variant (B.1.351), Brazil variant (P.1), and UK variant (B.1.1.7).

Key Points: 
  • B.1.351 S-Trimer demonstrated broad neutralization against the original SARS-CoV-2 strain and variants of concern, specifically the South African variant (B.1.351), Brazil variant (P.1), and UK variant (B.1.1.7).
  • Clover is at the forefront of vaccine R&D utilizing our proprietary Trimer-Tag technology and is the first company to disclose preclinical data demonstrating that a modified protein-based COVID-19 vaccine candidate can potentially induce broad neutralization against the original SARS-CoV-2 strain and variants of concern," said Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals.
  • As the SARS-CoV-2 virus mutates and additional data emerges, we are prepared to innovate and develop next-generation COVID-19 vaccines.
  • Any forward-looking statement made by us in this document speaks only as of the date on which it is made.